Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (NASDAQ:EWTX) announced inducement equity grants on November 28, 2025 related to a new non-executive hire. The company granted a stock option to purchase 26,250 shares under its 2024 Inducement Equity Incentive Plan.

The option exercise price is $26.04 per share (equal to the closing price on the grant date). Vesting is 25% after one year and then 1/48th monthly thereafter, subject to continued service. Grants were made as inducements under Nasdaq Listing Rule 5635(c)(4).

BOULDER, Colo., Dec. 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 28, 2025, Edgewise granted an inducement stock option to purchase a total of 26,250 shares of Edgewise's common stock to a new non-executive employee in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").    

The inducement stock option has an exercise price of $26.04 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

The inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302629652.html

SOURCE Edgewise Therapeutics

FAQ

What did Edgewise (EWTX) grant on November 28, 2025?

Edgewise granted an inducement stock option to purchase 26,250 shares to a new non-executive employee.

What is the exercise price of the Edgewise (EWTX) inducement option?

The exercise price is $26.04 per share, equal to the closing price on the grant date.

How does the Edgewise (EWTX) inducement option vest?

It vests 25% after one year of employment and then 1/48th monthly thereafter, subject to continued service.

Under which plan was the Edgewise (EWTX) award granted?

The award was granted under the company's 2024 Inducement Equity Incentive Plan.

Why did Edgewise (EWTX) grant the inducement option?

The grant was made as an inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).